Preconceptional antithyroid peroxidase antibodies, but not thyroid-stimulating hormone, are associated with decreased live birth rates in infertile women

In infertile women, preconceptional thyroid-stimulating hormone 2.5 mIU/L is not associated with reproductive outcomes; however, anti-thyroid peroxidase antibodies are associated with increased risk of miscarriage and decreased probability of live birth.

Like Comment

Volume 108, Issue 5, Pages 843–850


Aimee Seungdamrong, M.D., Anne Z. Steiner, M.D., M.P.H., Clarisa R. Gracia, M.D., M.S.C.E., Richard S. Legro, M.D., Michael P. Diamond, M.D., Christos Coutifaris, M.D., Ph.D., William D. Schlaff, M.D., Peter Casson, M.D., Gregory M. Christman, M.D., Randal D. Robinson, M.D., Hao Huang, M.D., M.P.H., Ruben Alvero, M.D., Karl R. Hansen, M.D., Ph.D., Susan Jin, M.P.H., Esther Eisenberg, M.D., M.P.H., Heping Zhang, Ph.D., Nanette Santoro, M.D. for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Reproductive Medicine Network



To study whether preconceptual thyroid-stimulating hormone (TSH) and antithyroid peroxidase (TPO) antibodies are associated with poor reproductive outcomes in infertile women.


Secondary analysis of data from two multicenter, randomized, controlled trials conducted by the Reproductive Medicine Network of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Multivariable logistic regression analyses were performed to assess the association between preconceptual TSH levels and anti-TPO antibodies.


Not applicable.


Serum samples from 1,468 infertile women were utilized.



Main Outcome Measure(s)

Cumulative conception, clinical pregnancy, miscarriage, and live birth rates were calculated.


Conception, clinical pregnancy, miscarriage, and live birth rates did not differ between patients with TSH ≥2.5 mIU/L vs. TSH < 2.5 mIU/L. Women with anti-TPO antibodies had similar conception rates (33.3% vs. 36.3%) but higher miscarriage rates (43.9% vs. 25.3%) and lower live birth rates (17.1% vs. 25.4%) than those without anti-TPO antibodies. Adjusted, multivariable logistic regression models confirmed elevated odds of miscarriage (odds ratio 2.17, 95% confidence interval 1.12–4.22) and lower odds of live birth (oddr ratio 0.58, 95% confidence interval 0.35–0.96) in patients with anti-TPO antibodies.


In infertile women, preconceptional TSH ≥2.5 mIU/L is not associated with adverse reproductive outcomes; however, anti-TPO antibodies are associated with increased risk of miscarriage and decreased probability of live birth.

Clinical Trial Registration Number

PPCOS II NCT00719186; AMIGOS NCT01044862.

Read the full text here.

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.